Triple Hit Lymphoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT05908409) | IDP Discovery Pharma S.L. | 2023-06-05 |
| XPO-1 in Combination With RCHOP for DH/TH Lymphoma (NCT05974085) | Zhejiang Cancer Hospital | 2022-08-01 |
Track Triple Hit Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.